Q2-osavuosiraportti
83 päivää sitten‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
1 802
Myynti
Määrä
1 100
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 5.6. | |
| 2024 Q4-osavuosiraportti | 10.4. | |
| 2024 Q2-osavuosiraportti | 29.8.2024 | |
| Merkintäoikeusanti | 20.6.2024 |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 t sittenGrok is positive and talks about a price target up to 120. ### Important Disclaimer I am not a financial advisor, and this is not personal investment advice. Stock investments always involve risk, including the possibility of losing all or part of your investment. Always do your own research, assess your risk tolerance, and consult a licensed advisor before making decisions. The information here is based on available data as of November 19, 2025, and may change rapidly. ### Current status of Circio Holding ASA (ticker: CRNA.OL) Circio Holding is a Norwegian biotechnology company that focuses on gene therapy and RNA platforms, including through its circVec technology. The company is listed on Euronext Oslo with ticker CRNA.OL. - **Current share price**: 1.63 NOK (as of last update November 19, 2025). This represents a sharp increase of over 65% from yesterday's closing price of 0.99 NOK. Today's opening was 1.51 NOK, with a trading volume of over 22 million shares – significantly higher than normal, indicating strong market interest. - **Market capitalization**: Approx. 234 million NOK. - **Key figures**: - EPS (earnings per share, last 12 months): -2.49 NOK (negative, which is common for growth-focused biotech companies in the development phase). - P/E ratio: Not available (due to losses). - Beta: 1.60 (high volatility – the stock fluctuates more than the general market). The stock has been volatile over the last year, with an increase of approx. 3.5% over 52 weeks, but with large fluctuations related to news about clinical progress and partnerships. ### Recent news and development Circio has had several positive updates in November 2025, which seem to be driving today's price increase: - **November 18**: Circio enters into a fully funded feasibility study with a large global pharmaceutical player. This is an important partnership that can accelerate the development of their circVec RNA platform for gene therapy. The study is fully funded by the partner, which reduces the company's costs and risk. - **November 17**: Invitation to webcast on November 24, where CTO Dr. Thomas B. Hansen will present the latest results from the circVec platform, including in vitro and in vivo data showing up to 40 times better performance than conventional AAV methods. The presentation will take place at the ESGCT Congress (European Society of Gene & Cell Therapy) in 2025. - Other updates include the registration of a share capital increase after the conversion of convertible bonds, which strengthens the balance sheet. These news items indicate progress in the core business, but the biotech sector is high-risk with dependence on clinical results and regulatory approvals. ### Analysts' views and forecasts Analysts are generally positive, but with variation: - **Consensus**: 86% of 7 analysts recommend "buy", based on the potential of the gene therapy platform. - **Price forecasts**: Average 12-month target price varies, but includes updates such as an increase to 120 NOK (60% upward adjustment) and a downward adjustment to 48 NOK (32% reduction). With today's price of 1.63 NOK, this indicates significant upside potential – but also uncertainty. - **Expected break-even**: Pushed back to 2026, which reflects continued losses in the near future. Technical analysis shows mixed signals: Some indicators point to "buy" in the short term due to momentum, while others are neutral or "sell" due to volatility. ### Should you buy now? - **Potential benefits**: Today's partnership news and upcoming presentation could drive further upside if the market reacts positively. The company has innovative technology in a growing market for gene therapy, and analysts' optimism supports a bullish view. - **Risks**: High volatility (beta 1.6), negative earnings, and dependence on clinical milestones. Biotech stocks can fall sharply on negative news, such as delays or failed studies. Market capitalization is low (small cap), which amplifies fluctuations. - **My assessment**: With the recent rally and positive news, it could be an exciting time for risk-tolerant investors who believe in the technology – but preferably wait for the webcast on November 24 for more data. Diversify and only invest what you can afford to lose. For more in-depth info, check sources like Yahoo Finance, Investing.com or Circio's website. Good luck! If you have more details about your portfolio, I can help with general analysis.- ·2 t sittenTrades among the 50 largest shareholders last registered trading day 17-18 Nov Buy Tor Arne Storkås up 50K Sell Nordnet life insurance down 70K 49 out of 50 hold or increase. Atlas remains steady with its 23.56 mill last trading day. Atlas has only sold 300K during the last week
·12 t sitten · MuokattuGood week we are in. Message yesterday, message today, Jefferies London 18-20 Nov, Update Circio presentation 24.11, and DnB Healthcare Conference 25.11 Oslo with Wikmann.·11 t sittenAvidity Biosciences by Novartis, which was recently announced: Novartis buys Avidity for 12 billion USD. Some comments on how this might affect the potential of Circio (CRNA): 🔍 Why this acquisition is relevant Avidity has an RNA platform (“Antibody Oligonucleotide Conjugates” or AOC) that allows them to deliver oligonucleotides / RNA to muscle tissue. This shows that large pharmaceutical companies (like Novartis) are willing to pay very high sums for new RNA technologies — it strengthens the “validation” of RNA therapies in general. It provides a parallel to Circio's technology: even though circRNA is different from AOCs, it shows that there is great commercial interest and high willingness to pay for advanced RNA platforms. Scenario Value Realistic probability Early acquisition 2–5 billion NOK 40% Avidity-light 8–20 billion NOK 45% Full Avidity 30–120 billion NOK 15%- ·12 t sittentekinvestor Mcap is low. It will take some time before the market digests the development, so one will probably see further upside in the coming days. Circio should at least now be at 3 - 4 kr in my opinion and mcap around 500 mill. Even that is low in the bio-world. Debt-free company with patented poc technology and agreement Big P should be a bet for many.
·12 t sittenIt's quite possible Atlas has done its part to keep it under 2kr. How many Shares do they hold now, I wonder. 18 mill??
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
83 päivää sitten‧37 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenGrok is positive and talks about a price target up to 120. ### Important Disclaimer I am not a financial advisor, and this is not personal investment advice. Stock investments always involve risk, including the possibility of losing all or part of your investment. Always do your own research, assess your risk tolerance, and consult a licensed advisor before making decisions. The information here is based on available data as of November 19, 2025, and may change rapidly. ### Current status of Circio Holding ASA (ticker: CRNA.OL) Circio Holding is a Norwegian biotechnology company that focuses on gene therapy and RNA platforms, including through its circVec technology. The company is listed on Euronext Oslo with ticker CRNA.OL. - **Current share price**: 1.63 NOK (as of last update November 19, 2025). This represents a sharp increase of over 65% from yesterday's closing price of 0.99 NOK. Today's opening was 1.51 NOK, with a trading volume of over 22 million shares – significantly higher than normal, indicating strong market interest. - **Market capitalization**: Approx. 234 million NOK. - **Key figures**: - EPS (earnings per share, last 12 months): -2.49 NOK (negative, which is common for growth-focused biotech companies in the development phase). - P/E ratio: Not available (due to losses). - Beta: 1.60 (high volatility – the stock fluctuates more than the general market). The stock has been volatile over the last year, with an increase of approx. 3.5% over 52 weeks, but with large fluctuations related to news about clinical progress and partnerships. ### Recent news and development Circio has had several positive updates in November 2025, which seem to be driving today's price increase: - **November 18**: Circio enters into a fully funded feasibility study with a large global pharmaceutical player. This is an important partnership that can accelerate the development of their circVec RNA platform for gene therapy. The study is fully funded by the partner, which reduces the company's costs and risk. - **November 17**: Invitation to webcast on November 24, where CTO Dr. Thomas B. Hansen will present the latest results from the circVec platform, including in vitro and in vivo data showing up to 40 times better performance than conventional AAV methods. The presentation will take place at the ESGCT Congress (European Society of Gene & Cell Therapy) in 2025. - Other updates include the registration of a share capital increase after the conversion of convertible bonds, which strengthens the balance sheet. These news items indicate progress in the core business, but the biotech sector is high-risk with dependence on clinical results and regulatory approvals. ### Analysts' views and forecasts Analysts are generally positive, but with variation: - **Consensus**: 86% of 7 analysts recommend "buy", based on the potential of the gene therapy platform. - **Price forecasts**: Average 12-month target price varies, but includes updates such as an increase to 120 NOK (60% upward adjustment) and a downward adjustment to 48 NOK (32% reduction). With today's price of 1.63 NOK, this indicates significant upside potential – but also uncertainty. - **Expected break-even**: Pushed back to 2026, which reflects continued losses in the near future. Technical analysis shows mixed signals: Some indicators point to "buy" in the short term due to momentum, while others are neutral or "sell" due to volatility. ### Should you buy now? - **Potential benefits**: Today's partnership news and upcoming presentation could drive further upside if the market reacts positively. The company has innovative technology in a growing market for gene therapy, and analysts' optimism supports a bullish view. - **Risks**: High volatility (beta 1.6), negative earnings, and dependence on clinical milestones. Biotech stocks can fall sharply on negative news, such as delays or failed studies. Market capitalization is low (small cap), which amplifies fluctuations. - **My assessment**: With the recent rally and positive news, it could be an exciting time for risk-tolerant investors who believe in the technology – but preferably wait for the webcast on November 24 for more data. Diversify and only invest what you can afford to lose. For more in-depth info, check sources like Yahoo Finance, Investing.com or Circio's website. Good luck! If you have more details about your portfolio, I can help with general analysis.
- ·2 t sittenTrades among the 50 largest shareholders last registered trading day 17-18 Nov Buy Tor Arne Storkås up 50K Sell Nordnet life insurance down 70K 49 out of 50 hold or increase. Atlas remains steady with its 23.56 mill last trading day. Atlas has only sold 300K during the last week
- ·12 t sitten · MuokattuGood week we are in. Message yesterday, message today, Jefferies London 18-20 Nov, Update Circio presentation 24.11, and DnB Healthcare Conference 25.11 Oslo with Wikmann.·11 t sittenAvidity Biosciences by Novartis, which was recently announced: Novartis buys Avidity for 12 billion USD. Some comments on how this might affect the potential of Circio (CRNA): 🔍 Why this acquisition is relevant Avidity has an RNA platform (“Antibody Oligonucleotide Conjugates” or AOC) that allows them to deliver oligonucleotides / RNA to muscle tissue. This shows that large pharmaceutical companies (like Novartis) are willing to pay very high sums for new RNA technologies — it strengthens the “validation” of RNA therapies in general. It provides a parallel to Circio's technology: even though circRNA is different from AOCs, it shows that there is great commercial interest and high willingness to pay for advanced RNA platforms. Scenario Value Realistic probability Early acquisition 2–5 billion NOK 40% Avidity-light 8–20 billion NOK 45% Full Avidity 30–120 billion NOK 15%
- ·12 t sittentekinvestor Mcap is low. It will take some time before the market digests the development, so one will probably see further upside in the coming days. Circio should at least now be at 3 - 4 kr in my opinion and mcap around 500 mill. Even that is low in the bio-world. Debt-free company with patented poc technology and agreement Big P should be a bet for many.·12 t sittenIt's quite possible Atlas has done its part to keep it under 2kr. How many Shares do they hold now, I wonder. 18 mill??
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
1 802
Myynti
Määrä
1 100
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 5.6. | |
| 2024 Q4-osavuosiraportti | 10.4. | |
| 2024 Q2-osavuosiraportti | 29.8.2024 | |
| Merkintäoikeusanti | 20.6.2024 |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
83 päivää sitten‧37 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 28.8. | |
| 2024 Yhtiökokous | 5.6. | |
| 2024 Q4-osavuosiraportti | 10.4. | |
| 2024 Q2-osavuosiraportti | 29.8.2024 | |
| Merkintäoikeusanti | 20.6.2024 |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenGrok is positive and talks about a price target up to 120. ### Important Disclaimer I am not a financial advisor, and this is not personal investment advice. Stock investments always involve risk, including the possibility of losing all or part of your investment. Always do your own research, assess your risk tolerance, and consult a licensed advisor before making decisions. The information here is based on available data as of November 19, 2025, and may change rapidly. ### Current status of Circio Holding ASA (ticker: CRNA.OL) Circio Holding is a Norwegian biotechnology company that focuses on gene therapy and RNA platforms, including through its circVec technology. The company is listed on Euronext Oslo with ticker CRNA.OL. - **Current share price**: 1.63 NOK (as of last update November 19, 2025). This represents a sharp increase of over 65% from yesterday's closing price of 0.99 NOK. Today's opening was 1.51 NOK, with a trading volume of over 22 million shares – significantly higher than normal, indicating strong market interest. - **Market capitalization**: Approx. 234 million NOK. - **Key figures**: - EPS (earnings per share, last 12 months): -2.49 NOK (negative, which is common for growth-focused biotech companies in the development phase). - P/E ratio: Not available (due to losses). - Beta: 1.60 (high volatility – the stock fluctuates more than the general market). The stock has been volatile over the last year, with an increase of approx. 3.5% over 52 weeks, but with large fluctuations related to news about clinical progress and partnerships. ### Recent news and development Circio has had several positive updates in November 2025, which seem to be driving today's price increase: - **November 18**: Circio enters into a fully funded feasibility study with a large global pharmaceutical player. This is an important partnership that can accelerate the development of their circVec RNA platform for gene therapy. The study is fully funded by the partner, which reduces the company's costs and risk. - **November 17**: Invitation to webcast on November 24, where CTO Dr. Thomas B. Hansen will present the latest results from the circVec platform, including in vitro and in vivo data showing up to 40 times better performance than conventional AAV methods. The presentation will take place at the ESGCT Congress (European Society of Gene & Cell Therapy) in 2025. - Other updates include the registration of a share capital increase after the conversion of convertible bonds, which strengthens the balance sheet. These news items indicate progress in the core business, but the biotech sector is high-risk with dependence on clinical results and regulatory approvals. ### Analysts' views and forecasts Analysts are generally positive, but with variation: - **Consensus**: 86% of 7 analysts recommend "buy", based on the potential of the gene therapy platform. - **Price forecasts**: Average 12-month target price varies, but includes updates such as an increase to 120 NOK (60% upward adjustment) and a downward adjustment to 48 NOK (32% reduction). With today's price of 1.63 NOK, this indicates significant upside potential – but also uncertainty. - **Expected break-even**: Pushed back to 2026, which reflects continued losses in the near future. Technical analysis shows mixed signals: Some indicators point to "buy" in the short term due to momentum, while others are neutral or "sell" due to volatility. ### Should you buy now? - **Potential benefits**: Today's partnership news and upcoming presentation could drive further upside if the market reacts positively. The company has innovative technology in a growing market for gene therapy, and analysts' optimism supports a bullish view. - **Risks**: High volatility (beta 1.6), negative earnings, and dependence on clinical milestones. Biotech stocks can fall sharply on negative news, such as delays or failed studies. Market capitalization is low (small cap), which amplifies fluctuations. - **My assessment**: With the recent rally and positive news, it could be an exciting time for risk-tolerant investors who believe in the technology – but preferably wait for the webcast on November 24 for more data. Diversify and only invest what you can afford to lose. For more in-depth info, check sources like Yahoo Finance, Investing.com or Circio's website. Good luck! If you have more details about your portfolio, I can help with general analysis.
- ·2 t sittenTrades among the 50 largest shareholders last registered trading day 17-18 Nov Buy Tor Arne Storkås up 50K Sell Nordnet life insurance down 70K 49 out of 50 hold or increase. Atlas remains steady with its 23.56 mill last trading day. Atlas has only sold 300K during the last week
- ·12 t sitten · MuokattuGood week we are in. Message yesterday, message today, Jefferies London 18-20 Nov, Update Circio presentation 24.11, and DnB Healthcare Conference 25.11 Oslo with Wikmann.·11 t sittenAvidity Biosciences by Novartis, which was recently announced: Novartis buys Avidity for 12 billion USD. Some comments on how this might affect the potential of Circio (CRNA): 🔍 Why this acquisition is relevant Avidity has an RNA platform (“Antibody Oligonucleotide Conjugates” or AOC) that allows them to deliver oligonucleotides / RNA to muscle tissue. This shows that large pharmaceutical companies (like Novartis) are willing to pay very high sums for new RNA technologies — it strengthens the “validation” of RNA therapies in general. It provides a parallel to Circio's technology: even though circRNA is different from AOCs, it shows that there is great commercial interest and high willingness to pay for advanced RNA platforms. Scenario Value Realistic probability Early acquisition 2–5 billion NOK 40% Avidity-light 8–20 billion NOK 45% Full Avidity 30–120 billion NOK 15%
- ·12 t sittentekinvestor Mcap is low. It will take some time before the market digests the development, so one will probably see further upside in the coming days. Circio should at least now be at 3 - 4 kr in my opinion and mcap around 500 mill. Even that is low in the bio-world. Debt-free company with patented poc technology and agreement Big P should be a bet for many.·12 t sittenIt's quite possible Atlas has done its part to keep it under 2kr. How many Shares do they hold now, I wonder. 18 mill??
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
1 802
Myynti
Määrä
1 100
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
-VWAP
Alin
-Vaihto ()
VWAP
Ylin
-Alin
-Vaihto ()
Välittäjätilasto
Dataa ei löytynyt